|Bid||25.17 x 800|
|Ask||0.00 x 36900|
|Day's Range||30.18 - 30.46|
|52 Week Range||24.54 - 30.84|
|PE Ratio (TTM)||400.79|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Yahoo Finance's Jared Blikre joins Seana Smith from the New York Stock Exchange to discuss the latest market moves.
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after Boeing reported first quarter earnings, beating estimates and raising full year guidance.
Zacks.com highlights: General Motors, Boston Scientific, Lam Research, NRG Energy and Celanese
The equity markets continued to breathe easy as the U.S.-China trade concerns abated with President Trump pledging support for the beleaguered Chinese telecom firm, ZTE, and the Qualcomm-NXP merger review process getting a roll-on with urgency from the top administration of China. A high ROE ensures that the company is reinvesting its cash at a high rate of return. ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
This takes a look at the gynecological mesh, how it has affected women it was placed in, and the 48,000 lawsuits concerning it. The first bit of bad publicity for Boston Scientific is what has been happening to the gynecological mesh over time. The report then looks at how Boston Scientific makes the gynecological mesh.
An increasingly common cardiovascular procedure using a device made by several medical technology companies was no better than drug therapy at preventing deaths, strokes and certain other complications, a new study found. The outcome of the trial raises questions about the procedure, known as catheter ablation, to treat patients with atrial fibrillation. Abbott Laboratories, Johnson & Johnson, Medtronic PLC and Boston Scientific Corp. make the device used in the procedure.
Boston Scientific Corporation (NYSE:BSX) delivered a less impressive 1.59% ROE over the past year, compared to the 11.43% return generated by its industry. Though BSX’s recent performance is underwhelming, itRead More...
On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.
(Continued from Prior Part)ABT’s Medical Device business In 1Q18, Abbott Laboratories (ABT) registered sales of $7.4 billion, representing YoY (year-over-year) growth of ~16.7%. The company’s Medical Device segment registered strong growth and contributed ~37.0% to the company’s total sales, the highest of all four of its segments. ABT’s Medical Device segment sales came in at ~$2.7 billion in 1Q18. On a reported basis, the segment’s sales growth was ~14.6% on a YoY basis. However, on an organic basis, the segment’s sales increased ~9.4%. ...
On April 18, Abbott Laboratories (ABT) released its 1Q18 earnings results. The company registered revenues of $7.4 billion, which represents YoY (year-over-year) growth of ~16.7%. These sales results exceeded analysts’ estimates.
On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.
Abbott Laboratories (ABT) reported its 1Q18 results on April 18. Let’s look at Wall Street analysts’ recommendations for ABT stock after its earnings release. On May 2, a Reuters survey noted that 20 brokerage firms were tracking ABT. Of these firms, 16 analysts recommended a “buy” or “strong buy.” The rest of the firms gave a “hold” rating on the stock. None of the firms gave a “sell” recommendation for Abbott Laboratories.
On April 25, Thermo Fisher Scientific (TMO) announced its earnings results for 1Q18, which ended on March 31. Its revenues grew ~23% to ~$5.9 billion YoY (year-over-year). The sales results came in ahead of analysts’ estimate of ~$5.6 billion.
On April 25, Boston Scientific announced its 1Q18 earnings results. Boston Scientific’s results exceeded analysts’ estimates and the company guidance. During the earnings release, Boston Scientific updated its outlook for fiscal 2018. The company expects to register fiscal 2018 sales of $9.75 billion–$9.9 billion. The EPS (earnings per share) in fiscal 2018 is expected to be $1.37–$1.41.
Boston Scientific rose Wednesday after quarterly sales and adjusted profit beat, but investors are still waiting for an update on its heart valves.
Boston Scientific Corp raised its full-year forecast on Wednesday after reporting stronger-than-expected growth across its businesses, soothing fears that it was losing share in the lucrative market for heart valves. The company, which lags behind Medtronic Plc and Edwards Lifesciences Corp in the heart valves market, is pinning its hopes on its updated Lotus device, set for launch in 2019, following the withdrawal of an earlier version from Europe last year.
For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. InvestorsRead More...
Boston Scientific Corp. (BSX) on Wednesday reported first-quarter net income of $298 million. On a per-share basis, the Marlborough, Massachusetts-based company said it had net income of 21 cents. Earnings, ...
U.S. medical device maker Boston Scientific Corp reported a 10 percent rise in first-quarter net sales on Wednesday, helped by higher demand for its products, including pacemakers and heart valves. Net ...